DexCom, Inc. (NASDAQ:DXCM) Given Average Rating of “Moderate Buy” by Analysts

DexCom, Inc. (NASDAQ:DXCM) has earned an average rating of “Moderate Buy” from the eighteen analysts that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $98.00.

Several equities analysts have recently commented on DXCM shares. Canaccord Genuity Group boosted their price objective on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Oppenheimer decreased their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Citigroup boosted their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Sanford C. Bernstein boosted their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th.

DexCom Price Performance

Shares of DexCom stock opened at $77.19 on Friday. The stock’s 50-day simple moving average is $73.58 and its 200-day simple moving average is $84.99. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a market capitalization of $30.15 billion, a price-to-earnings ratio of 46.22, a PEG ratio of 2.46 and a beta of 1.12. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Insider Activity

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after acquiring an additional 214,136 shares in the last quarter. Jennison Associates LLC boosted its position in DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after acquiring an additional 6,544,102 shares in the last quarter. Legal & General Group Plc boosted its position in DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after acquiring an additional 49,076 shares in the last quarter. Groupama Asset Managment boosted its position in DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock valued at $1,912,000 after acquiring an additional 31,358 shares in the last quarter. Finally, Westfield Capital Management Co. LP boosted its position in DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after acquiring an additional 876,739 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.